Resorcinol derivatives

1. A compound having the structure of Formula II:

or a pharmaceutically acceptable salt, or prodrug thereof, wherein:

X is C;

R 2 -R 3 are each hydroxyl;

R 4 -R 5 are each independently selected from the group consisting of hydrogen, deuterium, and hydroxyl;

R 6 is selected from the group consisting of a (C 1 -C 12 )alkyl, a hetero(C 1 -C 11 )alkyl, a (C 1 -C 12 )alkenyl, a hetero(C 1 -C 11 )alkenyl, a (C 1 -C 12 )alkynyl, and a hetero(C 1 -C 11 )alkynyl;

R 10 -R 19 are each independently selected from the group consisting of hydrogen or deuterium; and

R 20 is an optionally substituted heterocycle containing 4 or 5 ring atoms.

2. The compound of claim 1 , wherein R 6 is selected from the group consisting of methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, isopropyl, sec-butyl, (1-methyl)butyl, (1-methyl)pentyl, (1-methyl)hexyl, (1-methyl)heptyl, (1,1-dimethyl)propyl, (1,1-dimethyl)butyl, (1,1-dimethyl)pentyl, (1,1-dimethyl)hexyl, (1,1-dimethyl)heptyl, (1,2-dimethyl)propyl, (1,2-dimethyl)butyl, (1,2-dimethyl)pentyl, (1,2-dimethyl)hexyl, (1,2-dimethyl)heptyl, (1,3-dimethyl)butyl, (1,3-dimethyl)pentyl, (1,3-dimethyl)hexyl, (1,3-dimethyl)heptyl, (1,4-dimethyl)pentyl, (1,4-dimethyl)hexyl, (1,4-dimethyl)heptyl, (1,5-dimethyl)hexyl, (1,5-dimethyl)heptyl, (1,6-dimethyl)heptyl, (1,2-diethyl)butyl, (1,2-diethyl)pentyl, (1,2-diethyl)hexyl, (1,2-diethyl)heptyl, (1,2-diethyl)pentyl, (1,3-diethyl)pentyl, (1,3-diethyl)hexyl, (1,3-diethyl)heptyl, (1,4-diethyl)pentyl, (1,4-diethyl)hexyl, (1,4-diethyl)heptyl, (1,5-diethyl)hexyl, (1,5-diethyl)heptyl, (1,6-diethyl)heptyl, (1,2,3-trimethyl)butyl, (1,1,2-trimethyl)butyl, (1,1,3-trimethyl)butyl, (1,2,3-trimethyl)pentyl, (1,1,2-trimethyl)pentyl, (1,1,3-trimethyl)pentyl, (1,2,4-trimethyl)pentyl, (1,3,4-trimethyl)pentyl, (1,1,4-trimethyl)pentyl, (1,2,3-trimethyl)hexyl, (1,1,2-trimethyl)hexyl, (1,1,3-trimethyl)hexyl, (1,2,4-trimethyl)hexyl, (1,2,5-trimethyl)hexyl, (1,1,4-trimethyl)hexyl, (2,3,4-trimethyl)hexyl, (2,3,5-trimethyl)hexyl, (1,1,5-trimethyl)hexyl, (1,2,3-trimethyl)heptyl, (1,1,2-trimethyl)heptyl, (1,1,3-trimethyl)heptyl, (1,2,4-trimethyl)heptyl, (1,1,5-trimethyl)heptyl, (1,1,6-trimethyl)heptyl, (1,2,5-trimethyl)heptyl, (1,2,6-trimethyl)heptyl, (2,3,4-trimethyl)heptyl, (2,3,5-trimethyl)heptyl, (2,3,6-trimethyl)heptyl, (2,4,5-trimethyl)heptyl, (2,4,6-trimethyl)heptyl, (3,4,5-trimethyl)heptyl, (3,4,6-trimethyl)heptyl, and (4,5,6-trimethyl)heptyl.

3. The compound of claim 1 , wherein the optionally substituted heterocycle is selected from the group consisting of:

4. The compound of claim 1 , wherein

X is C,

R 2 -R 3 are each hydroxyl;

R 4 -R 5 are each independently selected from the group consisting of hydrogen;

R 6 is selected from the group consisting of a (C 1 -C 12 )alkyl, a hetero(C 1 -C 11 )alkyl, a (C 1 -C 12 )alkenyl, a hetero(C 1 -C 11 )alkenyl, a (C 1 -C 12 )alkynyl, and a hetero(C 1 -C 11 )alkynyl;

R 10 -R 19 are hydrogen; and

R 20 is

5. A pharmaceutical composition comprising the compound of claim 1 .

6. The pharmaceutical composition of claim 5 , wherein the composition further comprises an additional therapeutic agent.

7. The pharmaceutical composition of claim 6 , wherein the additional therapeutic agent is Δ 9 -tetrahydrocannabinol (“THC”) or a THC derivative.

8. The pharmaceutical composition of claim 7 , wherein the THC derivative is selected from the group consisting of Δ 9 -tetrahydrocannabinol-C 4 , Δ 9 -tetrahydrocannabivarin, tetrahydrocannabiorcol, Δ 9 -tetrahydro-cannabinolic acid A, Δ 9 -tetrahydro-cannabinolic acid B, Δ 9 -tetrahydro-cannabinolic acid-C 4 A, Δ 9 -tetrahydro-cannabinolic acid-C 4 B, Δ 9 -tetrahydro-cannabivarinic acid A, Δ 9 -tetrahydro-cannabiorcolic acid A, Δ 9 -tetrahydro-cannabiorcolic acid B, (−)-Δ 8 -trans-(6aR,10aR)-Δ 8 -tetrahydrocannabinol, (−)-Δ 8 -trans-(6aR,10aR)-tetrahydrocannabinolic acid A, and (−)-(6aS,10aR)-Δ 9 -tetrahydrocannabinol.

9. The pharmaceutical composition of claim 6 , wherein the additional therapeutic agent is selected from the group consisting of alkylating agents, cancer immunotherapy monoclonal antibodies, anti-metabolites, mitotic inhibitors, anti-tumor antibiotics, topoisomerase inhibitors, photosensitizers, tyrosine kinase inhibitors, anti-cancer agents, chemotherapeutic agents, anti-migraine treatments, anti-tussives, mucolytics, decongestants, anti-allergic non-steroidals, expectorants, anti-histamine treatments, anti-retroviral agents, CYP3A inhibitors, CYP3A inducers, protease inhibitors, adrenergic agonists, anti-cholinergics, mast cell stabilizers, xanthines, leukotriene antagonists, glucocorticoid treatments, antibacterial agents, antifungal agents, sepsis treatments, steroidals, local or general anesthetics, NSAIDS, NRIs, DARIs, SNRIs, sedatives, NDRIs, SNDRIs, monoamine oxidase inhibitors, hypothalamic phoshpholipids, anti-emetics, ECE inhibitors, opioids, thromboxane receptor antagonists, potassium channel openers, thrombin inhibitors, growth factor inhibitors, anti-platelet agents, P2Y(AC) antagonists, anti-coagulants, low molecular weight heparins, Factor Vla inhibitors, Factor Xa inhibitors, renin inhibitors, NEP inhibitors, vasopepsidase inhibitors, squalene synthetase inhibitors, anti-atherosclerotic agents, MTP inhibitors, calcium channel blockers, potassium channel activators, alpha-muscarinic agents, beta-muscarinic agents, anti-arrhythmic agents, diuretics, thrombolytic agents, anti-diabetic agents, mineralocorticoid receptor antagonists, growth hormone secretagogues, aP2 inhibitors, phophodiesterase inhibitors, anti-inflammatories, anti-proliferatives, antibiotics, farnesyl-protein transferase inhibitors, hormonal agents, plant-derived products, epipodophyllotoxins, taxanes, prenyl-protein transferase inhibitors, anti-TNF antibodies and soluble TNF receptors, and Cyclooxygenase-2 inhibitors.

10. The pharmaceutical composition of claim 9 , wherein the additional therapeutic agent is selected from the group consisting of alkylating agents, cancer immunotherapy monoclonal antibodies, anti-metabolites, mitotic inhibitors, anti-tumor antibiotics, topisomerase inhibitors, photosensitizers, tyrosine kinase inhibitors, anti-cancer agents, and chemotherapeutic agents.

11. The pharmaceutical composition of claim 10 , wherein the additional therapeutic agent is an anti-cancer agent.

12. The pharmaceutical composition of claim 10 , wherein the anti-cancer agent is paclitaxel and/or temozolomide.

13. A method for modulating helix-loop-helix Id protein expression, cell proliferation, cell invasion, metastasis or a combination thereof in vivo and/or in vitro by administering a compound of claim 1 .

14. A method for treating a disease or disorder in a subject, comprising administering to a subject a therapeutically effective amount of a compound of claim 1 , wherein the disease or disorder can be ameliorated by inhibiting the expression of an Id polypeptide, by activating cannabinoid type 2 (“CB 2 ”) receptors or a combination thereof.

15. The method of claim 14 , wherein the disease or disorder is selected from the group consisting of cancer, chronic pancreatitis, psoriasis, neoplasms, angiomas, endometriosis, obesity, age-related macular degeneration, retinopathies, restenosis, scaring, fibrogenesis, fibrosis, cardiac remodeling, pulmonary fibrosis, scleroderma, failure associated with myocardial infarction, keloids, fibroid tumors, Alzheimer's Disease, Parkinson's Disease, age related dementia, Huntington's Disease, and amyotrophic lateral sclerosis.